Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M35,325Revenue $M2,234Net Margin (%)26.0Z-Score26.5
Enterprise Value $M33,528EPS $3.3Operating Margin %33.7F-Score8
P/E(ttm))53.6Cash Flow Per Share $0.8Pre-tax Margin (%)33.8Higher ROA y-yY
Price/Book10.110-y EBITDA Growth Rate %0Quick Ratio4.3Cash flow > EarningsN
Price/Sales15.95-y EBITDA Growth Rate %52.3Current Ratio4.6Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %63.8ROA % (ttm)15.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)19.0Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M202ROI % (ttm)16.0Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNJoel Greenblatt 2014-12-31 Add0.13%$159.46 - $200.79
($185.68)
$ 174.75-6%Add 4665.74%85,974
ALXNRon Baron 2014-12-31 Add$159.46 - $200.79
($185.68)
$ 174.75-6%Add 41.92%18,366
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 174.756%Reduce -89.45%1,804
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 174.756%Add 27.56%12,941
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 174.7510%Add 240.11%17,094
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 174.759%New holding10,218
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 174.759%New holding5,026
ALXNJoel Greenblatt 2013-03-31 Sold Out -0.07%$83.39 - $102.57
($93.13)
$ 174.7547%Sold Out0
ALXNJoel Greenblatt 2012-12-31 Buy 0.07%$87.97 - $118.15
($98.27)
$ 174.7544%New holding12,977
ALXNGeorge Soros 2012-06-30 Sold Out -0.07%$83.74 - $98.82
($91.04)
$ 174.7548%Sold Out0
ALXNGeorge Soros 2012-03-31 Buy 0.07%$70.29 - $94.31
($75.85)
$ 174.7557%New holding50,000
ALXNJoel Greenblatt 2011-09-30 Sold Out -0.0882%$47.81 - $66.99
($56.19)
$ 174.7568%Sold Out0
ALXNJoel Greenblatt 2011-06-30 Buy 0.09%$44.61 - $52.195
($47.91)
$ 174.7573%New holding13,417
ALXNGeorge Soros 2011-06-30 Sold Out $44.61 - $52.195
($47.91)
$ 174.7573%Sold Out0
ALXNGeorge Soros 2011-03-31 Add$20.14 - $24.93
($22.51)
$ 174.7587%Add 90.48%16,000
ALXNGeorge Soros 2010-12-31 Reduce$31.78 - $41.17
($36.65)
$ 174.7579%Reduce -87.61%4,200
ALXNGeorge Soros 2010-09-30 Buy 0.03%$24.99 - $32.49
($28.22)
$ 174.7584%New holding33,900
ALXNGeorge Soros 2010-06-30 Sold Out -0.17%$24.31 - $28.34
($26.54)
$ 174.7585%Sold Out0
ALXNGeorge Soros 2010-03-31 Add0.06%$22.75 - $27.7
($24.88)
$ 174.7586%Add 51.77%214,000
ALXNGeorge Soros 2009-12-31 Buy 0.1%$21.65 - $24.33
($22.8)
$ 174.7587%New holding141,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELL LEONARDCEO 2015-03-19Sell15,952$188.07-3.67view
Sinha VikasEVP & CFO 2015-03-02Sell487$180.340.45view
O'Neill JulieEVP. Global Operations 2015-03-02Sell11,665$101.4978.5view
MACKAY MARTINEVP & Global Head of R&D 2015-03-02Sell370$180.340.45view
Moriarty John BEVP & General Counsel 2015-03-02Sell280$180.340.45view
Islam SaqibEVP, Chief Strat & Port. Off. 2015-03-02Sell228$180.340.45view
Carmichael ClareEVP, Chief HR Officer 2015-03-02Sell706$180.340.45view
Hallal DavidCOO 2015-03-02Sell730$180.340.45view
BELL LEONARDCEO 2015-03-02Sell1,230$180.340.45view
Sinha VikasEVP & CFO 2015-02-10Sell1,985$171.155.85view

Press Releases about ALXN :

Quarterly/Annual Reports about ALXN:

News about ALXN:

Articles On GuruFocus.com
Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 26 2013 
CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 


More From Other Websites
ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Apr 24 2015
Biogen Earnings Preview: What To Look For Apr 23 2015
Alexion Pharmaceuticals (ALXN) Earnings Report: Q1 2015 Conference Call Transcript Apr 23 2015
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 23 2015
Alexion Pharmaceuticals (ALXN) Stock Fell Today on Missed Earnings, Weak Guidance Apr 23 2015
Alexion Misses Q1 Earnings Estimates, Keeps 2015 Outlook - Analyst Blog Apr 23 2015
Alexion (ALXN) Misses on Q1 Earnings, Maintains Outlook - Tale of the Tape Apr 23 2015
Q1 2015 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open Apr 23 2015
Alexion Reports First Quarter 2015 Results Apr 23 2015
Alexion misses 1Q profit forecasts Apr 23 2015
Alexion misses 1Q profit forecasts Apr 23 2015
6:34 am Alexion Pharma misses by $0.03, beats on revs; guides FY15 EPS below consensus, revs below... Apr 23 2015
Alexion Reports First Quarter 2015 Results Apr 23 2015
Forget Google: 5 Top Stocks With Earnings Thursday Apr 22 2015
Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog Apr 21 2015
Should Gilead Sciences Buy Vertex? Bernstein Says Yes, Maxim Says No Apr 21 2015
The Zacks Analyst Blog Highlights: Medicines Co., Tekmira, GW Pharmaceuticals, Biogen and Alexion -... Apr 16 2015
Former Teva CEO's new gig at Ovid Therapeutics Apr 16 2015
Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog Apr 13 2015
Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies... Apr 13 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK